Safety of etoricoxib in patients with reactions to NSAIDs

Journal of Investigational Allergology and Clinical Immunology

Volumn 18, Issue 3, 2008, Pages 163-167

  Quercia, Oliviero ^a   Emiliani, F ^a   Foschi, F G ^a   Stefanini, G F ^a  

^a Hospital of Faenza   (Italy)

Author keywords

Anaphylactic reaction; Asthma; Cutaneous reaction; Etoricoxib; NSAID intolerance

Indexed keywords

DICLOFENAC; ETORICOXIB; FLURBIPROFEN; IBUPROFEN; INDOMETACIN; KETOPROFEN; KETOROLAC; MELOXICAM; NAPROXEN; NORAMIDOPYRINE; PIROXICAM; PLACEBO; PROPYPHENAZONE; TENOXICAM;

ADULT; ANAPHYLACTIC SHOCK; ANGIONEUROTIC EDEMA; ARTICLE; ASTHMA; CONTROLLED STUDY; DRUG ERUPTION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTPATIENT DEPARTMENT; PRURITUS; RESPIRATORY TRACT DISEASE; RHINITIS; SKIN MANIFESTATION; URTICARIA;

ADMINISTRATION, ORAL; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; FEMALE; HUMANS; MALE; MIDDLE AGED; PYRIDINES; SULFONES;

EID: 45749096979     PISSN: 10189068     EISSN: 16980808     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Settipane GA. Aspirin and allergic diseases. Ann J Med. 1983;74:102-10.
2. Kasper L, Sladek K, Duplaga M, Bochenek G, Liebhard G, Glaudisz U Malolepszy J, Szczeklik A. Prevalence of asthma with aspirin hypersensitivity in the adult population of Poland. Allergy. 2003;58:1064-6.
3. Fu JY, Masferrer JL, Seibert K, Raz A, Needleman P. The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. J Biol Chem. 1990;265:16737-40.
4. Kujubu DA, Fletcher BS, Varnum BC, Lim RW, Herschman HR. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss T3 cells, encodes novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem. 1991;266:12866-72.
5. Süleyman H, Demircan B, Karagöz Y. Anti-inflammatory and side effects of cyclooxygenase inhibitors. Pharmacol Rep. 2007;59:247-58.
6. Tacconelli S, Capone ML, Patrignani P. Clinical pharmacology of novel selective COX-2 Inhibitors. Curr Pharm Design. 2004;10:1-13.
7. Fitzgerald GA. Coxibs and cardiovascular disease. NEJM. 2004;351:1709-11.
8. Topol EJ, Falk GW. A coxib a day won't keep the doctor away. Lancet. 2004;364:639-40.
9. Mukhereje D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA. 2001;286:954-59.
10. Sanchez-Borges M, Caballero-Fonseca F, Capriles-Hulett A. Safety of etoricoxib, a new cyclooxygenase 2 inhibitor in patients with nonsteroidal anti-inflammatory drug-induced urticaria and angioedema. Ann Allergy Asthma Immunol. 2005;95(2):154-8.
11. Zhang J, Ding EL, Song Y. Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials. JAMA. 2006;296(13):1619-32.
12. Aldington S, Shirtcvcliffe P, Weatherall M, Beasley R. Systematic review and meta-analysis of the risk of major cardiovascular events with etoricoxib therapy. N Z Med J. 2005;118(1223):U1684.
13. Cannon CP, Curtis SP, Fitzgerald GA, Krum H, Kaur A, Bolognese JA, Reicin AS, Bombardier C, Weinblatt ME, van der Heijde D, Edermann E, Laine L, MEDAL Steering Committee. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet. 2006;368:1771-81.
14. Jouzeau JY, Terlain B, Abid A, Nedelec E, Netter P. Cyclooxygenase isoenzymes. How recent finding affect thinking about nonsteroidal antiinflammatory drugs. Drugs. 1997;53:563-592.
15. Pairet M, van Fyn J. Experimental models used to investigate the differential inhibition of cycloossigenase-1 and cycloossigenase-2 by non-steroidal antiinflammatory drugs. Inflamm Res. 1998;47:S93-101.
16. Brooks P, Emery P, Evans JF, Fenner H, Hawkey CJ, Patrono C, Smolen J, Breedveld F, Day R, Dougados M, Ehrich EW, Gijon-Baños J, Kvien TK, van Rijswijk MH, Warner T, Zeidler H. Interpreting the clinical significance of the differential inhibition of cycloossigenase-1 and cyclooxigenase-2. Rheumatology. 1999;38:779-88.
17. Riendeau D, Percival MD, Brideau C, Charleston S, Dube D, Ethier D, Falgueyret JP, Friesen RW, Gordon R, Greg G, Guay J, Mancini J, Ouellet M, Wong E, Xu L, Boyce S, Visco D, Girard Y., Prasit P, Zamboni R., Rodger IW, Gresse M, Ford-Hutchison AW, Young RN, Chan CC. Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J. Pharmacol. Ex. Ther. 2001;296:558-566.
18. Szczeklik A, Gryglewski RJ, Czerniawska-Mysik G. Clinical patterns of hypersensitivity to non steroidal anti-inflammatory drugs and their pathogenesis. J Allergy Clin Immunol. 1977;60:276-84.
19. Aberer W, Bircher A, Romano A, Blanca M, Campi P, Fernandez J, Brockow K, Pichler WJ, Demoly P, European Network for Drug Allergy (ENDA), EAACI interest group on drug hypersensitivity. Drug provocation testing in the diagnosis of drug hypersensitivity reactions: general considerations. Allergy. 2003;58(9):854-63.
20. Ortolani C, D'Amato G, Giannetti A, Marone G, Moscato G, Meneghini A. Memorandum SIAIC nella diagnosi di allergia/intolleranza ai farmaci. Giorn It Allergol Clin Immunol. 1998;8:568-95.
21. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol. 1971;231(25):232-5.
22. Wood AJJ. The Coxibs: selective inhibitors of cyclooxygenasis-2. NEJM. 2001; 345:433-42..
23. Mitchell JA, Akarasereenont P, Thiemermann C, Flower RJ, Vane JR. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase Proc Natl Acad Sci U S A. 1993 ;90:11693-7.
24. Meade EA, Smith WL, DeWitt DL. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J Biol Chem. 1993;268:6610-4.
25. Quiralte J, Delgado J, Saenez de San Pedro B, Lopez-Pascual E, Nieto MA, Ortega N, Florido JF, Conde J. Safety of the new selective cyclooxygenase type 2 inhibitors rofecoxib and celecoxib in patients with anaphylactoid reactions to nonsteroidal anti-inflammatory drugs. Ann Allergy Asthma Immunol. 2004;93(4):360-4.
26. Baybek S, Celik G, Ozer F, Mungan D, Misirligil Z. Safety of selective COX-2 inhibitors in aspirin/nonsteroidal anti-inflammatory drug-intolerant patients: comparison of nimesulide, meloxicam, and rofecoxib. J Asthma. 2004;41(1):67-75.
27. Perrone MR, Artesiani MC, Viola M, Gaeta F, Caringi M, Quarantino D, Romano A. Tolerability of rofecoxib in patients with adverse reactions to nonsteroidal anti-inflammatory drugs: a study of 216 patients and literature review. Int Arch Allergy Immunol. 2003;132(1):82-6.
28. Liccardi G, Cazzola M, De Giglio C, Manfredi D, Piscitelli E, D'Amato M, D'Amato G. Safety of celecoxib in patients with adverse skin reactions to acetaminophen (paracetamol) and other non-steroidal anti-inflammatory drugs. J Investig Allergol Clin Immunol. 2005;15(4):249-53.
29. Grob M, Pichler WJ, Wuthrich B. Anaphylaxis to celecoxib. Allergy. 2002;57:264-5.
30. Fontaine C, Bousquet PJ, Demoly P. Anaphylactic shock caused by a selective allergy to celecoxib, with no allergy to rofecoxib or sulfamethoxazole. J Allergy Clin Immunol. 2005;115(3):633-4.
31. Schellenberg RR, Isserow SH. Anaphylactoid reaction to a cyclooxygenase 2 inhibitor in a patient who had a reaction to a cyclooxygenase 1 inhibitor. NEJM. 2001;345:1856.
32. Szczeklik A, Nizankowska E, Bochenek G, Nagraba K, Mejza F, Swierczynska M. Safety of a specific COX-2 inhibitor in aspirin-induced asthma. Clin Exp Allergy. 2001;31(2):219-25.
33. Martin-Garcia C, Hinojosa M, Berbges P, Camacho E, Garcia-Rodriguez R, Alfaya T. Celecoxib, a highly selective COX-2 inhibitor, is safe in aspirin-induced asthma patients. J Investig Allergol Clin Immunol. 2003;13(1):20-5.
34. Zembowicz A, Mastalerz L, Setkowicz M, Radziszewski W, Szczeklik A. Safety of cyclooxygenase-2 inhibitors and increased leukotriene synthesis in chronic idiopathic urticaria with sensitivity to non steroidal anti-inflammatory drugs. Arch Dermatol. 2003;139:1577-82.
35. Matucci A, Parronchi P, Vultaggio A, Rossi O, Brugnolo F, Maggi E, Romagnani S. Partial safety of the new COX-2 inhibitor rofecoxib in NSAIDs high sensitive patients. Allergy. 2004;59:1133-4.
36. Nettis E, Colanardi MC, Ferrannini A, Vacca A, Tursi A. Short-term tolerability of etoricoxib in patients with cutaneous hypersensitivity reactions to nonsteroidal anti-inflammatory drugs. Ann Allergy Asthma Immunol. 2005;95(5):438-42.
37. El Miedany Y, Youssef S, Ahmed I, El Gaafary M. Safety of etoricoxib, a specific cyclooxygenase-2 inhibitor, in asthmatic patients with aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol. 2006;97(1):105-9.